The National Cancer Act — also known as the war on cancer — celebrates its 40th anniversary today. If you want to take a quick spin through the highlights of progress against the disease over those four decades, the American Society of Clinical Oncology has put together a timeline of major milestones , by decade and type of cancer. (For example, in 1998, the FDA approved Herceptin for women with advanced breast cancer whose disease overproduces a certain protein.) For an overview of what’s been accomplished since 1971, and what remains to be done, we chatted with Michael Link , president of ASCO and a pediatric oncologist at Stanford University. “The most important thing to point out is the return on investment in lab research,” he says, noting advances in understanding cancer at the molecular level. “Cancers that look the same under the microscope are different,” he says, with different behaviors, prognoses and treatment options. “If you understand what is making it tick, you can interfere with that machinery with a very specific drug,” he says. (He points to Novartis’ Gleevec as a key example.) Link also notes that cure rates for some cancers, such as pediatric cancers, testicular cancer and non-Hodgkin’s lymphoma, have improved. Death rates for all cancers have fallen by 22% for men and 14% for women over the
The rest is here:
‘War on Cancer’ Celebrates 40th Anniversary; What’s Next?


John


